SCHEMBL1031028

SCHEMBL1031028

Nc1nc(N)c(-c2ccccc2)c(O)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 6/20 0.56
HEXA P06865 1/20 0.56
HEXB P07686 1/20 0.56
ADORA2A P29274 2/20 0.47
ADORA1 P30542 2/20 0.47
POLB P06746 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
ADORA2B P29275 1/20 0.47
KDM4E B2RXH2 2/20 0.46
MAPK1 P28482 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
MAPT P10636 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CSNK1A1 P48729 1/20 0.46
CLK4 Q9HAZ1 1/20 0.46
PIK3CG P48736 1/20 0.44
DCPS Q96C86 1/20 0.44
JAK2 O60674 1/20 0.43
GMNN O75496 1/20 0.43
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12496375 0.90 ADORA2A (0.52) DHFRHEXAHEXBADORA2AADORA1
SCHEMBL7162150 0.85 DHFR (0.66) DHFRHEXAHEXBADORA2AADORA1
SCHEMBL13402261 0.81 MAPK1 (0.43) DHFRHEXAHEXBADORA2AADORA1
Methane SCHEMBL11818737 0.79 HEXA (0.57) DHFRHEXAHEXBADORA2AADORA1
SCHEMBL2473930 0.78 DHFR (0.58) DHFRHEXAHEXBADORA2AADORA1
SCHEMBL16540957 0.77 L3MBTL1 (0.45) DHFRHEXAHEXBADORA2AADORA1
SCHEMBL16540959 0.77 POLB (0.46) DHFRHEXAHEXBADORA2AADORA1
SCHEMBL3500167 0.76 DHFR (0.61) DHFRHEXAHEXBADORA2AKDM4E
Hydrochloric Acid SCHEMBL15487768 0.76 DHFR (0.56) DHFRHEXAHEXBADORA2AADORA1
SCHEMBL27631682 0.74 ADORA1 (0.61) DHFRHEXAHEXBADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1805966-B Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs INST OF ORGANIC CHENISTRY AND 2013-03-13 CN disclosed
EP-1644389-B1 PYRIMIDINE COMPOUNDS HAVING PHOSPHONATE GROUPS AS ANTIVIRAL NUCLEOTIDE ANALOGS ACAD OF SCIENCE CZECH REPUBLIC (CZ) 2011-01-19 EP disclosed
US-20060241081-A1 Novel compounds and methods for therapy INSTITUTE OF ORGANIC CHEMISTRY 2006-10-26 US disclosed
US-7115592-B2 Phosphonate substituted pyrimidine compounds and methods for therapy INSTITUTE OF ORGANIC CHEMISTRY (CZ) 2006-10-03 US disclosed
EP-1644389-A1 PYRIMIDINE COMPOUNDS HAVING PHOSPHONATE GROUPS AS ANTIVIRAL NUCLEOTIDE ANALOGS INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) 2006-04-12 EP disclosed
US-20050075318-A1 Novel compounds and methods for therapy INSTITUTE OF ORGANIC CHENISTRY AND BIOCHEMISTRY ACADEMYOF SCIENCES OF THE CZECH REPUBLIC 2005-04-07 US disclosed
WO-2004111064-A1 PYRIMIDINE COMPOUNDS HAVING PHOSPHONATE GROUPS AS ANTIVIRAL NUCLEOTIDE ANALOGS INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY, ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075318-A1 Novel compounds and methods for therapy ZC3HAV1, IFNAR1, EIF2AK2 DHFR 72/4885HEXA 1925/4885HEXB 1621/4885
US-20060241081-A1 Novel compounds and methods for therapy ZC3HAV1, IFNAR1, EIF2AK2 DHFR 72/4885HEXA 1925/4885HEXB 1621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.